Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(2R,6R)-Hydroxynorketamine in Healthy Volunteers
NCT04711005Phase 1Completed
- Sponsor
- National Institute of Mental Health
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of (2R,6R)-hydroxynorketamine in major depressive disorder (MDD) (10 arms), sponsored by National Institute of Mental Health. Primary endpoints: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability, Maximum Plasma Concentration and 3 more. Started Jan 2021; status: completed.
02
Drugs
(2R,6R)-hydroxynorketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04711005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711005.